Table 2.

Major studies of CSF biomarker to predict progression from MCI to AD published between 2004 and 2010.

Study	Year	Case	Follow-up	MCI to AD	Marker	Sensitivity	Specificity	Other
Hampel	2004	52 MCI 93 AD 10 cont	8.4 M	29/52 (56%)	Aβ42, †Tau	Aβ42 59% †Tau 83%	Aβ42 100% †Tau 90%	European cohort
Parnetti	2006	55 MCI 100 AD 14 DLB 11 FTD	1 Y	11/55 (20%) 38% of MCI has 2 marker abnormalities	Aβ42, †Tau, pTau181	2 biomarker abnormality in AD converters (91%)	Normal markers in stable MCI (88%)	Mayo Clinic Cohort
Hansson	2006	137 MCI 39 cont	4~7 Y	57 AD (42%) 21 nonAD dementia (15%) 56 stable MCI (41%)	Aβ42, †Tau, pTau181	Aβ42/†Tau 95% Aβ42/†Tau/ pTau181 95%	Aβ42/†Tau 83% Aβ42/†Tau/ pTau181 87%	Prospective study
Show	2009	100 AD 191 MCI 114 cont	1 Y	37/191 (19%)	Aβ42, †Tau, pTau181	Tau/Aβ42 predicted 89% of AD converters CSF Aβ42 highly correlated with brain pathology		US-ADNI
Mattsson	2009	750 MCI 529 AD 304 cont	>2 Y	271 AD/750 MCI (36%) 59 nonAD dementia/750 MCI	Aβ42, †Tau, pTau181	83%	73%	12 centers Europe/US
Visser	2009	60 SCI 37 naMCI 71 aMCI 89 cont	3 Y	8/22 CSF/AD naMCI (36%) 27/53 CSF/AD aMCI (51%)	Aβ42, †Tau, pTau181	CSF/AD was observed in control 31%, SCI 52%, naMCI 68%, aMCI 79% All AD had CSF/AD CSF/AD is a significant risk in aMCI		DESCRIPA study Europe study

SCI: subjective cognitive impairment; naMCI: nonamnesctic MCI; aMCI: amnestic MCI; CSF/AD: CSF AD profile (decreased Aβ42/increased tau).